MICROVUE^™ FGF-23 ELISA (C-Term)

The MICROVUE Human FGF-23 (C-Term) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.

Product Specifications

Citations	35
Specimen	Plasma or Cell Culture Supernatent, 200 µL
LLOQ	1.5 RU/mL
ULOQ	N/A
Assay Time	3.5 hours
Cross Reactivity	None

Technical Documents

Ordering Information

For Research Use Only. Not for use in diagnostic procedures.

Catalog Number	60-6100
Catalog Number (CE)
Size	96 wells/test
Price (USD)	$785.00
Price (EURO)	695,00 €

Contact us

US Phone	+1 (858) 552 1100
EU Phone	+353 (91) 412 474
US Email	customerservice@quidelortho.com
EU Email	EMEACustomerService@quidelortho.com

Specifications
Citations
Certificate of Analysis

Specifications

Description	The MICROVUE Human FGF-23 (C-Term) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.
Size	96 wells/test
Form	96 well plate with 12 eight-well strips in a resealable foil pouch
Specimen	Plasma or Cell Culture Supernatent, 200 µL
Limit of Detection (LOD)	1.5 RU/mL
Lower Limit of Quantitation (LLOQ)	1.5 RU/mL
Upper Limit of Quantitation (ULOQ)	N/A
Intra Assay	1.4 - 2.4%
Inter Assay	2.4 - 4.7%
Standards	6
Controls	2
Sample Values	N/A
Assay Time	3.5 hours
Cross Reactivity	None
Storage	Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components
Background	Fibroblast growth factor 23 (FGF-23), which is produced by bone cells, is a novel member of a large family of related proteins. Its gene encodes a 251 amino acid protein. The amino-terminal portion of FGF-23 (aa 1-24) is hydrophobic and is likely to serve as a signal peptide allowing its secretion into the blood circulation. Its carboxyl-terminal portion (aa 180-251) shares only limited amino acid homology with other members of the FGF family of proteins.

Citations

Title	Year	Applications	Sample Species	Sample	Sample Details
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease	2005	ELISA	Human	Serum
Determination of fibroblast growth factor 23	2009	ELISA	Human	Plasma
Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis	2009	ELISA	Human	HEK293 cells
Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis	2009	ELISA	Human	Plasma
Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease	2010	ELISA	Human	Plasma
Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease	2010	ELISA	Human	Serum
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active	2010	ELISA	Human	Plasma
The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease	2010	ELISA	Human	Plasma
Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature	2011	ELISA	Human	Serum
Early skeletal and biochemical alterations in pediatric chronic kidney disease	2012	ELISA	Human	Plasma
Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function	2012	ELISA	Human	Serum
Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients	2012	ELISA	Human	Serum	Chronic Kidney Disease
Biological variability of plasma intact and C-terminal FGF23 measurements	2012	ELISA	Human	Plasma
Intact fibroblast growth factor 23 and fragments in plasma from Gambian children	2013	ELISA	Human	Plasma
Novel SLC34A3 mutation causing hereditary hypophosphataemic rickets with hypercalciuria in a Gambian family	2013	ELISA	Human	Plasma
Associations among total and food additive phosphorus intake and carotid intima-media thickness--a cross-sectional study in a middle-aged population in Southern Finland	2013	ELISA	Human	Plasma
A low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients	2013	ELISA	Human	Serum
Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children	2013	ELISA	Human	Plasma
The use of fibroblast growth factor 23 testing in patients with kidney disease	2014	ELISA	Human	Plasma
Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin	2014	ELISA	Human	Plasma
Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients	2015	ELISA	Human	Plasma
Aortic Artery and Cardiac Valve Calcification are Associated with Mortality in Chinese Hemodialysis Patients: A 3.5 Years Follow-up	2015	ELISA	Human	Plasma	MHD
Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease	2016	ELISA	Human	Plasma	Acute Coronary Syndrome
C-Terminal to Intact Fibroblast Growth Factor 23 Ratio in Relation to Estimated Glomerular Filtration Rate in Elderly Population	2016	ELISA	Human	Plasma
Dietary phosphate supplement does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia	2016	ELISA	Human	Plasma
Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy	2016	ELISA	Human	Plasma
Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes	2018	ELISA	Human	Plasma	Diabetes
Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease	2018	ELISA	Human	Plasma	Acute Coronary Syndrome
Fibroblast Growth Factor 23-Induced Hypophosphatemia in Acute Leukemia	2018	ELISA	Human	Plasma
Aptamer-Based Proteomics Identifies Mortality-Associated Serum Biomarkers in Dialysis-Dependent AKI Patients	2018	ELISA	Human	Serum
The Heart and Kidney: Abnormal Phosphate Homeostasis Is Associated With Atherosclerosis	2018	ELISA	Human	Plasma
Plasma Fibroblast Growth Factor 23 Is Elevated in Pediatric Primary Hypertension	2019	ELISA	Human	Plasma	Hypertension (Children)
Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study	2019	ELISA	Human	Plasma
Tumor-induced osteomalacia: experience from three tertiary care centers in India	2019	ELISA	Human	Serum	Hypoparathyroidism
Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial	2020	ELISA	Human	Plasma	Chronic Kidney Disease
FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD: A Revisit With Mediation Analysis	2024	ELISA	Human	Plasma	Chronic Kidney Disease
Associations of Intact and C-Terminal FGF23 with Inflammatory Markers in Older Patients Affected by Advanced Chronic Kidney Disease	2024	ELISA	Human	Plasma	Chronic Kidney Disease
Fibroblast growth factor 23-mediated regulation of osteoporosis: Assessed via Mendelian randomization and in vitro study	2024	ELISA	Human	Serum	Osteoporosis
Blood concentrations of α-Klotho and FGF-23 exhibit no correlation with bone mineral density in elderly individuals	2024	ELISA	Human	Serum
Prostaglandin E(2) signaling through prostaglandin E receptor subtype 2 and Nurr1 induces fibroblast growth factor 23 production	2024	ELISA	Human	Serum
Carotid intima-media thickness, fibroblast growth factor 23, and mineral bone disorder in children with chronic kidney disease	2024	ELISA	Human	Plasma	Chronic Kidney Disease (Pediatric)
Controlled dietary phosphate loading in healthy young men elevates plasma phosphate and FGF23 levels	2024	ELISA	Human	Plasma
Association of Fibroblast Growth Factor 23 and Cardiac Mechanics in the Cardiovascular Health Study	2024	ELISA	Human	Plasma	Cardiac dysfunction
C-terminal FGF-23 production coupling with aldosterone via FAM20C and predicting cardiovascular events in primary aldosteronism	2025	ELISA	Human	Plasma	Cardiac dysfunction
Factors associated with phosphate homeostasis in children with beta-thalassemia major: An analytical cross sectional study from Pakistan	2025	ELISA	Human	Plasma	Beta-thalassemia
FGF-23 as a Biomarker for Carotid Plaque Vulnerability: A Systematic Review	2025	ELISA	Human	Serum	Carotid artery disease
Neurofibromatosis type I (NF1) and bone involvement in a pediatric setting: insights from FGF23 levels	2025	ELISA	Human	Serum	Neurofibromatosis
The vitamin D(3) hormone, 1,25(OH)(2)D(3), regulates fibroblast growth factor 23 (FGF23) production in human skin cells	2025	ELISA	Cell Culture		Neurofibromatosis
The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage	2025	ELISA	Human	Plasma
Changes in local mineral homeostasis facilitate the formation of benign and malignant testicular microcalcifications	2025	ELISA	Human	Testicular tissue
Increased Plasma Fibroblast Growth Factor 23 and In-hospital Acute Kidney Injury after Cardiac Surgery	2025	ELISA	Human	Plasma	Acute kidney injury
Fibroblast Growth Factor 23 Is a Strong Predictor of Adverse Events After Left Ventricular Assist Device Implantation	2025	ELISA	Human	Plasma	Heart Failure
iFGF23:cFGF23 Ratio Is a Questionable Diagnostic Marker for Distinguishing Between Acute and Chronic Kidney Disease	2025	ELISA	Human	Plasma	Chronic Kidney Disease
Serum fibroblast growth factor 23 and kidney injury molecule-1 in the prediction of acute kidney injury in critically-ill patients	2025	ELISA	Human	Serum	Acute kidney injury
FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial	2025	ELISA	Human	Plasma	Cardiac dysfunction
Association between Serum Glycerol-3-Phosphate and Fibroblast Growth Factor-23 in Nondiabetic Patients on Hemodialysis	2025	ELISA	Human	Serum	Dialysis
Site-specific inverse associations between FGF23 levels and marrow adiposity content at the proximal femur in post-menopausal women	2026	ELISA	Human	Serum
Fibroblast Growth Factor 23 Trajectories in Children and Association with CKD Progression: The CKD in Children Study	2026	ELISA	Human	Plasma	Chronic Kidney Disease (Pediatric)
Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post-Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho	2026	ELISA	Human	Serum	Myocardial infarction
Predicting atrial fibrillation after an acute coronary syndrome: insights from the BACS & BAMI study	2026	ELISA	Human	Plasma	Cardiac dysfunction
Age- and sex-specific reference values for phosphate homeostasis parameters-fibroblast growth factor 23 and soluble Klotho	2026	ELISA	Human	Plasma

Certificate of Analysis

Showing results for

No results found for

MICROVUE™ FGF-23 ELISA (C-Term)

The MICROVUE Human FGF-23 (C-Term) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.

Product Specifications

Ordering Information

Contact us

Specifications

Citations

Certificate of Analysis

MICROVUE^™ FGF-23 ELISA (C-Term)